Retatrutide
10mg vial
A$ 303Rp 3.400.000
A weight-loss compound that acts on three different receptors involved in appetite, fat storage, and blood sugar regulation. Studied for significant fat loss, reduced appetite, improved insulin sensitivity, and improvements in cholesterol markers.
Compound overview
What it is
Retatrutide is a triple agonist — it activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. GLP-1 and GIP work together to slow gastric emptying, reduce appetite signalling in the brain, and improve insulin secretion. The glucagon component adds a thermogenic and hepatic fat-burning dimension that single and dual agonists lack.
Within weeks of beginning a titrated protocol, most users report a marked reduction in baseline hunger and a shorter satiety window — feeling full on less food. Energy expenditure increases modestly from the glucagon effect. Blood glucose regulation improves, particularly post-meal spikes. Triglycerides and LDL typically decline over longer cycles.
Studied outcomes
- Up to 24% body weight reduction in phase 2 clinical trials over 48 weeks
- Significant reduction in fasting glucose and HbA1c
- Reduction in LDL cholesterol and triglycerides
- Improved insulin sensitivity independent of weight loss
- Reduction in liver fat (hepatic steatosis)
Suitability
Who it's for
- Significant weight loss goals where other interventions have plateaued
- Metabolic syndrome or insulin resistance alongside excess weight
- Type 2 diabetes management under practitioner supervision
- Clients who have not responded adequately to GLP-1 single agonists
Who should avoid it
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Pregnancy or breastfeeding
- Severe gastroparesis or active pancreatitis
- Those not prepared to commit to a careful titration schedule
Dosing guidance
Protocol guidance
Dose
Start at 0.5–1mg per week; titrate to tolerance. Research doses reached up to 12mg/week.
Frequency
Once weekly subcutaneous injection
Cycle length
12–48 weeks depending on goals; maintenance protocols vary
Route
Subcutaneous injection (abdomen, thigh, or upper arm)
Timing
Same day each week; time of day is not critical
Safety
Contraindications & cautions
- Titrate slowly — nausea is dose-dependent and manageable with gradual increases
- Monitor blood glucose if taking insulin or other diabetes medications — hypoglycaemia risk when combined
- Possible delay in gastric emptying — space oral medications accordingly
- Discontinue 4 weeks before planned surgery
- Not studied in those with a history of pancreatitis — use with caution
Stacking
Pairs well with
Targets visceral abdominal fat specifically via GH release — complements metabolic recomposition
Mitochondrial peptide that improves metabolic flexibility and insulin signalling — synergistic on glucose regulation
Supports cellular energy and mitochondrial function during caloric restriction and fat loss phases
Not medical advice. Not a substitute for medical care. Consult your licensed practitioner before beginning any protocol. Peptides are sold for research purposes only and are suitable for adults aged 18 years and over.